|
|
||||||||
State University of New York
and
Western New York Veterans Health Care System
Buffalo, New York
South Texas Veterans Health Care System
and
University of Texas Health Science Center at San Antonio
San Antonio, Texas
University of Michigan
Ann Arbor, Michigan
From the Authors:
We appreciate Dr. Singh's comments on our article (1). Although aminophylline, postural drainage, and chest physiotherapy may have a role in some patients with acute exacerbation, their benefits remain largely unproven, and we would therefore not recommend them for all patients with an acute exacerbation. We agree with the components of the treatment package for hospitalized patients mentioned by Dr. Singh. However, we believe this treatment should be individualized rather than provided in a standard package, in both outpatients and hospitalized patients.
FOOTNOTES
Conflict of Interest Statement: S.S. has received honoraria for consultancy, and less than $10,000 each from Bayer, Pfizer, GSK, Schering, Ortho McNeil, Sanofi-Aventis, and Oscient for lectures. He has received research funding from Bayer ($52,000) and GSK ($5,000). A.A. has participated as a speaker in scientific meetings or courses organized and financed by various pharmaceutical companies, including Boehringer Ingelheim, Bayer Pharma, Pfizer, GlaxoSmithKline (GSK), Sanofi-Aventis, Sepracor, and Altana. He has been a consultant for Boehringer Ingelheim, Bayer, Pfizer, GSK, Sanofi-Aventis, and Sepracor. He has been the principal investigator for research grants through the University of Texas Health Science Center at San Antonio, was paid for participating in multicenter clinical trials sponsored by Boehringer Ingelheim, Bayer Pharma, BART, Lilly, GSK, and the National Institutes of Health. F.J.M. is a consultant for Altana Pharma and has received compensation greater than $10,000. He has been a member of several advisory boards, continuing medical education committees, and the speaker's bureau for Boehringer Ingelheim, Pfizer, and GSK. His total compensation per company is greater than $10,000. In addition, he is on the advisory board for Novartis and the speaker's bureau for Sepracor and Astra, receiving less than $10,000 per company. He has been an investigator for industry-sponsored studies for GSK, Boehringer Ingelheim, and Actelion.
REFERENCES
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |